We have previously shown in DLBCL cell lines that CYCLON, as a downstream target of MYC, can be targeted by small molecule BET inhibitors, reducing CYCLON protein levels and mimicking the increased CD20 sensitivity associated with CYCLON knock-down [10]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.